PMID- 24118498
OWN - NLM
STAT- MEDLINE
DCOM- 20140731
LR  - 20131216
IS  - 1600-0609 (Electronic)
IS  - 0902-4441 (Linking)
VI  - 92
IP  - 1
DP  - 2014 Jan
TI  - MYC translocation partner gene determines survival of patients with large B-cell 
      lymphoma with MYC- or double-hit MYC/BCL2 translocations.
PG  - 42-8
LID - 10.1111/ejh.12212 [doi]
AB  - In large B-cell lymphoma (LBCL) MYC- and MYC/BCL2 double-hit (DH) translocations 
      have been associated with inferior survival. We hypothesised that the negative 
      prognostic impact of MYC translocation was determined by an immunoglobulin MYC 
      translocation partner gene (IG-MYC), as opposed to a non-immunoglobulin partner 
      gene (nonIG-MYC). In a prospective, unselected cohort of 237 LBCL patients MYC 
      and BCL2 translocations were identified by fluorescent in situ hybridisation 
      (FISH) with split probes. MYC translocation partner gene was identified by 
      IGH/MYC fusion probes and/or kappa/lambda split probes. Clinical data were 
      collected from patient files. MYC translocation was identified in 28/225 
      patients. IG-MYC translocation partner gene was identified in 12/24 patients. DH 
      translocation was identified in 23/228 patients. IG-MYC translocation partner 
      gene was identified in 9/19 DH patients. Neither MYC-nor DH translocation showed 
      correlation with survival. However, MYC translocation with IG-MYC translocation 
      partner gene was associated with worse OS compared with both MYC translocation 
      with nonIG-MYC translocation partner gene (P = 0.02) as well as absence of MYC 
      translocation (P = 0.03). In patients with DH a similar, however, stronger 
      correlation was seen (P = 0.003 and P = 0.0004 respectively). MYC - or DH 
      translocation with nonIG-MYC translocation partner gene was not associated with 
      worse overall survival (P = 0.2 and P = 0.3 respectively). Most patients received 
      Rituximab (86%) and CHOP/CHOP-like chemotherapy regimes (81%). We suggest that 
      prognostic stratification of LBCL patients by MYC and/or DH translocations should 
      include identification of MYC translocation partner gene because approximately 
      half of the cases harbour nonIG-MYC translocation partner genes with no or minor 
      influence on survival.
CI  - (c) 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Pedersen, Mette O
AU  - Pedersen MO
AD  - Department of Pathology, Herlev University Hospital, University of Copenhagen, 
      Herlev, Denmark.
FAU - Gang, Anne O
AU  - Gang AO
FAU - Poulsen, Tim S
AU  - Poulsen TS
FAU - Knudsen, Helle
AU  - Knudsen H
FAU - Lauritzen, Anne F
AU  - Lauritzen AF
FAU - Nielsen, Signe L
AU  - Nielsen SL
FAU - Klausen, Tobias W
AU  - Klausen TW
FAU - Norgaard, Peter
AU  - Norgaard P
LA  - eng
PT  - Journal Article
DEP - 20131111
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Genes, bcl-2
MH  - *Genes, myc
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/diagnosis/drug therapy/*genetics/*mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - *Translocation, Genetic
OTO - NOTNLM
OT  - BCL2 genes
OT  - MYC genes
OT  - MYC translocation partner genes
OT  - chromosomal translocation
OT  - diffuse large B-cell lymphoma
OT  - double-hit
EDAT- 2013/10/15 06:00
MHDA- 2014/08/01 06:00
CRDT- 2013/10/15 06:00
PHST- 2013/10/08 00:00 [accepted]
PHST- 2013/10/15 06:00 [entrez]
PHST- 2013/10/15 06:00 [pubmed]
PHST- 2014/08/01 06:00 [medline]
AID - 10.1111/ejh.12212 [doi]
PST - ppublish
SO  - Eur J Haematol. 2014 Jan;92(1):42-8. doi: 10.1111/ejh.12212. Epub 2013 Nov 11.